Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Cesare Berra"'
Autor:
Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, Stefano Del Prato, Angelo Avogaro, Anna Solini, Mariella Baldassarre, Agostino Consoli, Sara Morganet, Antonella Zugaro, Marco Giorgio Baroni, Francesco Andreozzi, Adriano Gatti, Stefano De Riu, Andrea Del Buono, Raffaella Aldigeri, Riccardo Bonadonna, Alessandra Dei Cas, Angela Vazzana, Monica Antonini, Valentina Moretti, Patrizia Li Volsi, Miranda Cesare, Giorgio Zanette, Silvia Carletti, Paola D'Angelo, Gaetano Leto, Frida Leonetti, Luca D'Onofrio, Ernesto Maddaloni, Raffaella Buzzetti, Simona Frontoni, Giselle Cavallo, Susanna Morano, Tiziana Filardi, Umberto Capece, Andrea Giaccari, Antonio C. Bossi, Giancarla Meregalli, Fabrizio Querci, Alessia Gaglio, Veronica Resi, Emanuela Orsi, Stefano Fazion, Ivano G. Franzetti, Cesare Berra, Silvia Manfrini, Gabriella Garrapa, Giulio Lucarelli, Lara Riccialdelli, Elena Tortato, Marco Zavattaro, Gianluca Aimaretti, Franco Cavalot, Guglielmo Beccuti, Fabio Broglio, Bruno Fattor, Giuliana Cazzetta, Olga Lamacchia, Anna Rauseo, Salvatore De Cosmo, Rosella Cau, Mariangela Ghiani, Antonino Di Benedetto, Antonino Di Pino, Salvatore Piro, Francesco Purrello, Lucia Frittitta, Agostino Milluzzo, Giuseppina Russo
Publikováno v:
The Lancet Regional Health. Europe, Vol 38, Iss , Pp 100847- (2024)
Summary: Background: Despite the overall improvement in care, people with type 2 diabetes (T2D) experience an excess risk of end-stage kidney disease. We evaluated the long-term effectiveness of dapagliflozin on kidney function and albuminuria in pat
Externí odkaz:
https://doaj.org/article/af262c8fdded4a0983a289dedffa98cc
Autor:
Maria Elena Lunati, Vincenzo Cimino, Davide Bernasconi, Alessandra Gandolfi, Paola Silvia Morpurgo, Camilla Tinari, Elisa Lazzaroni, Laura Baruffaldi, Milena Muratori, Laura Montefusco, Ida Pastore, Antonio Rossi, Ivano Giuseppe Franzetti, Fabrizio Muratori, Roberto Manfrini, Olga Eugenia Disoteo, Rosa Terranova, Paolo Desenzani, Angela Girelli, Renata Ghelardi, Francesca D’Addio, Moufida Ben Nasr, Cesare Berra, Franco Folli, Loredana Bucciarelli, Paolo Fiorina
Publikováno v:
Pharmacological Research, Vol 199, Iss , Pp 107040- (2024)
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor and semaglutide, a glucagon-like peptide 1 receptor agonist, have both demonstrated efficacy in glycemic control, reducing blood pressure, body weight, risk of renal and heart failure in type
Externí odkaz:
https://doaj.org/article/896fc8acef4049c186f0bd9af04fa581
Autor:
Elisa Lazzaroni, Maria Elena Lunati, Laura Montefusco, Ida Pastore, Enrica Chebat, Vincenzo Cimino, Paola Silvia Morpurgo, Milena Muratori, Laura Plebani, Andrea Bolla, Antonio Rossi, Luciana Vallone, Alessandra Gandolfi, Camilla Tinari, Francesca D’Addio, Moufida Ben Nasr, Cristian Loretelli, Cristiana Scaranna, Rosalia Bellante, Roberto Manfrini, Fabrizio Muratori, Ivano Franzetti, Emanuela Orsi, Carmine Gazzaruso, Renata Ghelardi, Paolo Desenzani, Stefano Genovese, Angela Girelli, Franco Folli, Cesare Berra, Paolo Fiorina
Publikováno v:
Pharmacological Research, Vol 183, Iss , Pp 106374- (2022)
Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardi
Externí odkaz:
https://doaj.org/article/bebdf59a7df04d4580f983cb409b28c8
Autor:
Maria Elena Lunati, Vincenzo Cimino, Alessandra Gandolfi, Matteo Trevisan, Laura Montefusco, Ida Pastore, Camilla Pace, Nazarena Betella, Giuseppe Favacchio, Monica Bulgheroni, Loredana Bucciarelli, Giulia Massari, Cristina Mascardi, Angela Girelli, Paola Silvia Morpurgo, Franco Folli, Livio Luzi, Marco Mirani, Basilio Pintaudi, Federico Bertuzzi, Cesare Berra, Paolo Fiorina
Publikováno v:
Pharmacological Research, Vol 183, Iss , Pp 106396- (2022)
Background and aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) may have important benefits for the elderly with type 2 diabetes (T2D), however some safety concerns still limit their use in patients over 70 years of age. The SOLD study (SGLT
Externí odkaz:
https://doaj.org/article/4a2c41cb4fed45eeadd7317aaca28290
Autor:
Alberto, Aglialoro, Roberto, Anichini, Angelo, Avogaro, Cristiana, Baggiore, Cesare, Berra, Riccardo, Bonadonna, Giuseppe, Corrao Salvatore Maria, Andrea, Da Porto, Lorenzo, De Candia, Alessandro, De Cosmo Salvatore, Graziano, Di Cianni, Gloria, Formoso, Gabriella, Garrapa, Mariangela, Ghiani, Francesco, Giorgino, Giacomo, Guaita, Ida, Maiorino Maria, Stefano, Masi, Monica, Modugno, Nicola, Morea
Publikováno v:
Acta Diabetologica; Oct2024, Vol. 61 Issue 10, p1267-1281, 15p
Autor:
null Raffaele Napoli, null Cesare Berra, null Andrei‐Mircea Catarig, null Chiara Di Loreto, null Emily Donatiello, null Tina Landsvig Berentzen, null Dario Pitocco, null Francesco Giorgino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aae78dd1ad4d78b1bb436fe914fdfa1b
https://doi.org/10.1111/dom.15020/v2/response1
https://doi.org/10.1111/dom.15020/v2/response1
Autor:
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, Chiara Di Loreto, Emily Donatiello, Tina Landsvig Berentzen, Dario Pitocco, Francesco Giorgino
Aims: SURE Italy, a multicentre, prospective, open-label, observational, real-world study, investigated once-weekly (OW) semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and methods: Adults with T2D and ≥1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7998f80bc279bd225aff36d6307322e6
https://hdl.handle.net/11588/913425
https://hdl.handle.net/11588/913425
Autor:
Giulia Bendotti, Laura Montefusco, Maria Elena Lunati, Vera Usuelli, Ida Pastore, Elisa Lazzaroni, Emma Assi, Andy Joe Seelam, Basset El Essawy, Jun Jang, Cristian Loretelli, Francesca D’Addio, Cesare Berra, Moufida Ben Nasr, GianVincenzo Zuccotti, Paolo Fiorina
Publikováno v:
Pharmacological research. 182
In the last few years, a great interest has emerged in investigating the pleiotropic effects of Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower plasma glucose and to induce weight loss has allowed them to be appr
Autor:
Francesca, D'Addio, Gianmarco, Sabiu, Vera, Usuelli, Emma, Assi, Ahmed, Abdelsalam, Anna, Maestroni, Andy Joe, Seelam, Moufida, Ben Nasr, Cristian, Loretelli, Davide, Mileto, Giada, Rossi, Ida, Pastore, Laura, Montefusco, Paola S, Morpurgo, Laura, Plebani, Antonio, Rossi, Enrica, Chebat, Andrea M, Bolla, Maria Elena, Lunati, Chiara, Mameli, Maddalena, Macedoni, Spinello, Antinori, Stefano, Rusconi, Maurizio, Gallieni, Cesare, Berra, Franco, Folli, Massimo, Galli, Maria Rita, Gismondo, Gianvincenzo, Zuccotti, Paolo, Fiorina
Patients with type 1 diabetes (T1D) may develop severe outcomes during coronavirus disease 2019 (COVID-19), but their ability to generate an immune response against the SARS-CoV-2 mRNA vaccines remains to be established. We evaluated the safety, immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87000ac1461dce99bc7fef6ac5b8c11d
https://doi.org/10.2337/figshare.19709308.v1
https://doi.org/10.2337/figshare.19709308.v1
Autor:
Chiara Di Loreto, Alessandra Di Lelio, Giuseppe Lucisano, Cesare Berra, Francesco Reggiani, Paola Ponzani, Maria Chiara Rossi, Paola Del Sindaco
Publikováno v:
Diabetes Therapy
Introduction Real-world evidence on the effectiveness and safety of insulin degludec (IDeg) in patients with diabetes is a priority. We have therefore evaluated the effectiveness and safety of IDeg, including impact on metabolic control, glycemic var